Ex vivo profiling of PD-1 blockade using organotypic tumor spheroids

Cancer Discovery

Volumn 8, Issue 2, 2018, Pages 196-215

  Jenkins, Russell W ^a,b   Aref, Amir R ^a   Lizotte, Patrick H ^a   Ivanova, Elena ^a   Stinson, Susanna ^c   Zhou, Chensheng W ^a   Bowden, Michaela ^a   Deng, Jiehui ^a   Liu, Hongye ^a,b   Miao, Diana ^a,d   He, Meng Xiao ^a,d,e   Walker, William ^a   Zhang, Gao ^f   Tian, Tian ^g   Cheng, Chaoran ^g   Wei, Zhi ^g   Palakurthi, Sangeetha ^a   Bittinger, Mark ^a   Vitzthum, Hans ^b   Kim, Jong Wook ^a,d   Merlino, Ashley ^a   Quinn, Max ^a   Venkataramani, Chandrasekar ^c   Kaplan, Joshua A ^c   Portell, Andrew ^a   Gokhale, Prafulla C ^a   Phillips, Bart ^c   Smart, Alicia ^a,d   Rotem, Asaf ^a   Jones, Robert E ^a   Keogh, Lauren ^a   Anguiano, Maria ^h   Stapleton, Lance ^c   Jia, Zhiheng ^c   Barzily Rokni, Michal ^b   Cañadas, Israel ^a   Thai, Tran C ^a   Hammond, Marc R ^b   Vlahos, Raven ^a   Wang, Eric S ^a   Zhang, Hua ^a   Li, Shuai ^a   Hanna, Glenn J ^a   Huang, Wei ^a   Hoang, Mai P ⁱ   Piris, Adriano ^j   Eliane, Jean Pierre ⁱ   Stemmer Rachamimov, Anat O ⁱ   Cameron, Lisa ^a   Su, Mei Ju ^a   Shah, Parin ^a   Izar, Benjamin ^a,d   Thakuria, Manisha ^a,j   LeBoeuf, Nicole R ^a,j   Rabinowits, Guilherme ^a   Gunda, Viswanath ⁱ   Parangi, Sareh ⁱ   Cleary, James M ^a   Miller, Brian C ^a   Kitajima, Shunsuke ^a   Thummalapalli, Rohit ^a   Miao, Benchun ^b   Barbie, Thanh U ^j   Sivathanu, Vivek ^k   Wong, Joshua ^a   Richards, William G ^j   Bueno, Raphael ^j   Yoon, Charles H ^j   Miret, Juan ^a   Herlyn, Meenhard ^f   Garraway, Levi A ^a   Van Allen, Eliezer M ^a,d   Freeman, Gordon J ^a   Kirschmeier, Paul T ^a   Lorch, Jochen H ^a   Ott, Patrick A ^a   Stephen Hodi, F ^a   Flaherty, Keith T ^b   Kamm, Roger D ^k   Boland, Genevieve M ⁱ   Wong, Kwok Kin ^a   Dornan, David ^c   Paweletz, Cloud Peter ^a   Barbie, David A ^a   more..

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c GILEAD SCIENCES   (United States)

^d MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^e The Wistar Institute ^*  (United States)

^f WISTAR INSTITUTE   (United States)

^g University Heights   (United States)

^h UNIVERSITY OF NAVARRA   (Spain)

ⁱ MASSACHUSETTS GENERAL HOSPITAL   (United States)

^j BRIGHAM AND WOMEN S HOSPITAL   (United States)

^k Massachusetts Institute of Technology   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CXCL13 CHEMOKINE; GILVETMAB; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; RECEPTOR TYPE TYROSINE PROTEIN PHOSPHATASE C; CYTOKINE; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; PROGRAMMED DEATH 1 RECEPTOR;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; CANCER TISSUE; CIRCULATING TUMOR CELL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOPHENOTYPING; MELANOMA; MICROFLUIDIC ANALYSIS; MUTATIONAL ANALYSIS; NEXT GENERATION SEQUENCING; NONHUMAN; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; SURVIVAL ANALYSIS; TUMOR MICROENVIRONMENT; TUMOR SPHEROID; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CULTURE TECHNIQUE; DRUG RESISTANCE; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; METABOLISM; MOUSE; MULTICELLULAR SPHEROID; TIME LAPSE IMAGING; TUMOR CELL CULTURE; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; CYTOKINES; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; MICE; MICROFLUIDIC ANALYTICAL TECHNIQUES; PROGRAMMED CELL DEATH 1 RECEPTOR; SPHEROIDS, CELLULAR; TIME-LAPSE IMAGING; TUMOR CELLS, CULTURED;

EID: 85041418590     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-17-0833     Document Type: Article

References (59)

1. Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 2015; 27: 450-61.
2. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12: 252-64.
3. Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell 2017; 168: 707-23.
4. Ribas A, Hamid O, Daud A, Hodi FS, Wolchok JD, Kefford R, et al. Association of pembrolizumab with tumor response and survival among patients with advanced melanoma. JAMA 2016; 315: 1600-9.
5. Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol 2015; 33: 1889-94.
6. Festino L, Botti G, Lorigan P, Masucci GV, Hipp JD, Horak CE, et al. Cancer treatment with anti-PD-1/PD-L1 agents: Is PD-L1 expression a biomarker for patient selection?. Drugs 2016; 76: 925-45.
7. Larkin J, Hodi FS, Wolchok JD. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015; 373: 1270-1.
8. Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 2015; 372: 2006-17.
9. O’Donnell JS, Long GV, Scolyer RA, Teng MW, Smyth MJ. Resistance to PD1/PDL1 checkpoint inhibition. Cancer Treat Rev 2017; 52: 71-81.
10. Pitt JM, Vetizou M, Daillere R, Roberti MP, Yamazaki T, Routy B, et al. Resistance mechanisms to immune-checkpoint blockade in cancer: tumor-intrinsic and -extrinsic factors. Immunity 2016; 44: 1255-69.
11. Taube JM, Young GD, McMiller TL, Chen S, Salas JT, Pritchard TS, et al. Differential expression of immune-regulatory genes associated with PD-L1 display in melanoma: implications for PD-1 pathway blockade. Clin Cancer Res 2015; 21: 3969-76.
12. Van Allen EM, Miao D, Schilling B, Shukla SA, Blank C, Zimmer L, et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 2015; 350: 207-11.
13. Ribas A, Shin DS, Zaretsky J, Frederiksen J, Cornish A, Avramis E, et al. PD-1 blockade expands intratumoral memory T cells. Cancer Immunol Res 2016; 4: 194-203.
14. Hugo W, Zaretsky JM, Sun L, Song C, Moreno BH, Hu-Lieskovan S, et al. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell 2016; 165: 35-44.
15. Smyth MJ, Ngiow SF, Ribas A, Teng MW. Combination cancer immunotherapies tailored to the tumour microenvironment. Nat Rev Clin Oncol 2016; 13: 143-58.
16. Chen PL, Roh W, Reuben A, Cooper ZA, Spencer CN, Prieto PA, et al. Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade. Cancer Discov 2016; 6: 827-37.
17. Friedman AA, Letai A, Fisher DE, Flaherty KT. Precision medicine for cancer with next-generation functional diagnostics. Nat Rev Cancer 2015; 15: 747-56.
18. Huang AC, Postow MA, Orlowski RJ, Mick R, Bengsch B, Manne S, et al. T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature 2017; 545: 60-5.
19. Anderson KG, Stromnes IM, Greenberg PD. Obstacles posed by the tumor microenvironment to T cell activity: a case for synergistic therapies. Cancer Cell 2017; 31: 311-25.
20. Yu M, Bardia A, Aceto N, Bersani F, Madden MW, Donaldson MC, et al. Cancer therapy. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility. Science 2014; 345: 216-20.
21. Gao D, Vela I, Sboner A, Iaquinta PJ, Karthaus WR, Gopalan A, et al. Organoid cultures derived from patients with advanced prostate cancer. Cell 2014; 159: 176-87.
22. Zitvogel L, Pitt JM, Daillere R, Smyth MJ, Kroemer G. Mouse models in oncoimmunology. Nat Rev Cancer 2016; 16: 759-73.
23. Aref AR, Huang RY, Yu W, Chua KN, Sun W, Tu TY, et al. Screening therapeutic EMT blocking agents in a three-dimensional microenvironment. Integr Biol (Camb) 2013; 5: 381-9.
24. Zhu Z, Aref AR, Cohoon TJ, Barbie TU, Imamura Y, Yang S, et al. Inhibition of KRAS-driven tumorigenicity by interruption of an autocrine cytokine circuit. Cancer Discov 2014; 4: 452-65.
25. Peggs KS, Quezada SA, Chambers CA, Korman AJ, Allison JP. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med 2009; 206: 1717-25.
26. Curran MA, Montalvo W, Yagita H, Allison JP. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A 2010; 107: 4275-80.
27. Woo SR, Turnis ME, Goldberg MV, Bankoti J, Selby M, Nirschl CJ, et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res 2012; 72: 917-27.
28. Duraiswamy J, Kaluza KM, Freeman GJ, Coukos G. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. Cancer Res 2013; 73: 3591-603.
29. Reardon DA, Gokhale PC, Klein SR, Ligon KL, Rodig SJ, Ramkissoon SH, et al. Glioblastoma eradication following immune checkpoint blockade in an orthotopic, immunocompetent model. Cancer Immunol Res 2016; 4: 124-35.
30. Peng W, Chen JQ, Liu C, Malu S, Creasy C, Tetzlaff MT, et al. Loss of PTEN promotes resistance to T cell-mediated immunotherapy. Cancer Discov 2016; 6: 202-16.
31. Benci JL, Xu B, Qiu Y, Wu TJ, Dada H, Twyman-Saint Victor C, et al. Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade. Cell 2016; 167: 1540-54 e12.
32. Vanneman M, Dranoff G. Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer 2012; 12: 237-51.
33. Yu J, Zhou X, Chang M, Nakaya M, Chang JH, Xiao Y, et al. Regulation of T-cell activation and migration by the kinase TBK1 during neuroinflammation. Nat Commun 2015; 6: 6074.
34. Zhang J, Feng H, Zhao J, Feldman ER, Chen SY, Yuan W, et al. IkappaB kinase epsilon is an NFATc1 kinase that inhibits T cell immune response. Cell Rep 2016; 16: 405-18.
35. Nghiem PT, Bhatia S, Lipson EJ, Kudchadkar RR, Miller NJ, Annamalai L, et al. PD-1 blockade with pembrolizumab in advanced Merkel-cell carcinoma. N Engl J Med 2016; 374: 2542-52.
36. Forster R, Davalos-Misslitz AC, Rot A. CCR7 and its ligands: balancing immunity and tolerance. Nat Rev Immunol 2008; 8: 362-71.
37. Bindea G, Mlecnik B, Tosolini M, Kirilovsky A, Waldner M, Obenauf AC, et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity 2013; 39: 782-95.
38. Cancer Genome Atlas N. Genomic classification of cutaneous melanoma. Cell 2015; 161: 1681-96.
39. Letai A. Functional precision cancer medicine-moving beyond pure genomics. Nat Med 2017; 23: 1028-35.
40. Hirt C, Papadimitropoulos A, Mele V, Muraro MG, Mengus C, Iezzi G, et al. “In vitro” 3D models of tumor-immune system interaction. Adv Drug Deliv Rev 2014; 79-80: 145-54.
41. Chang CH, Wang Y, Li R, Rossi DL, Liu D, Rossi EA, et al. Combination therapy with bispecific antibodies and PD-1 blockade enhances the antitumor potency of T cells. Cancer Res 2017; 77: 5384-94.
42. Hoffmann TK, Schirlau K, Sonkoly E, Brandau S, Lang S, Pivarcsi A, et al. A novel mechanism for anti-EGFR antibody action involves chemokine-mediated leukocyte infiltration. Int J Cancer 2009; 124: 2589-96.
43. Zboralski D, Hoehlig K, Eulberg D, Froemming A, Vater A. Increasing tumor-infiltrating T cells through inhibition of CXCL12 with NOX-A12 synergizes with PD-1 blockade. Cancer Immunol Res 2017; 10.1158/2326-6066.CIR-16-0303.
44. Lizotte PH, Jones RE, Keogh L, Ivanova E, Liu H, Awad MM, et al. Fine needle aspirate flow cytometric phenotyping characterizes immunosuppressive nature of the mesothelioma microenvironment. Sci Rep 2016; 6: 31745.
45. Charoentong P, Finotello F, Angelova M, Mayer C, Efremova M, Rieder D, et al. Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade. Cell Rep 2017; 18: 248-62.
46. Tirosh I, Izar B, Prakadan SM, Wadsworth MH 2nd, Treacy D, Trombetta JJ, et al. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science 2016; 352: 189-96.
47. Yu H, Shahsafaei A, Dorfman DM. Germinal-center T-helper-cell markers PD-1 and CXCL13 are both expressed by neoplastic cells in angioimmunoblastic T-cell lymphoma. Am J Clin Pathol 2009; 131: 33-41.
48. Gu-Trantien C, Loi S, Garaud S, Equeter C, Libin M, de Wind A, et al. CD4(+) follicular helper T cell infiltration predicts breast cancer survival. J Clin Invest 2013; 123: 2873-92.
49. Onder L, Danuser R, Scandella E, Firner S, Chai Q, Hehlgans T, et al. Endothelial cell-specific lymphotoxin-beta receptor signaling is critical for lymph node and high endothelial venule formation. J Exp Med 2013; 210: 465-73.
50. Allen E, Jabouille A, Rivera LB, Lodewijckx I, Missiaen R, Steri V, et al. Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation. Sci Transl Med 2017; 9. pii: eaak9679. doi: 10.1126/scitranslmed.aak9679.
51. Pitzalis C, Jones GW, Bombardieri M, Jones SA. Ectopic lymphoid-like structures in infection, cancer and autoimmunity. Nat Rev Immunol 2014; 14: 447-62.
52. Khaitan D, Chandna S, Arya MB, Dwarakanath BS. Establishment and characterization of multicellular spheroids from a human glioma cell line; Implications for tumor therapy. J Transl Med 2006; 4: 12.
53. Mueller-Klieser W, Freyer JP, Sutherland RM. Influence of glucose and oxygen supply conditions on the oxygenation of multicellular spheroids. Br J Cancer 1986; 53: 345-53.
54. Manguso RT, Pope HW, Zimmer MD, Brown FD, Yates KB, Miller BC, et al. In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target. Nature 2017; 10.1038/nature23270.
55. Xiao Y, Zou Q, Xie X, Liu T, Li HS, Jie Z, et al. The kinase TBK1 functions in dendritic cells to regulate T cell homeostasis, autoimmunity, and antitumor immunity. J Exp Med 2017; 214: 1493-507.
56. Liao Y, Smyth GK, Shi W. FeatureCounts: An efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics 2014; 30: 923-30.
57. Robinson MD, McCarthy DJ, Smyth GK. edgeR: a bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 2009; 26: 139-40.
58. Lizotte PH, Ivanova EV, Awad MM, Jones RE, Keogh L, Liu H, et al. Multiparametric profiling of non-small-cell lung cancers reveals distinct immunophenotypes. JCI Insight 2016; 1: e89014.
59. Deng R, Bumbaca D, Pastuskovas CV, Boswell CA, West D, Cowan KJ, et al. Preclinical pharmacokinetics, pharmacodynamics, tissue distribution, and tumor penetration of anti-PD-L1 monoclonal antibody, an immune checkpoint inhibitor. MAbs 2016; 8: 593-603.